This inventor holds 11 USPTO granted patents and 3 published patent applications. Top assignees: Funai Electric Company Ltd., Mitsubishi Tanabe Pharma Corporation, Sumitomo Chemical Company, Limited. Active years: 1978-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Niihama, JA (1978)
- Toyonaka, JP (1993)
- Daito, JP (2009)
- Osaka, JP (1993 - 2023)
Company Filing History:
5 out of 2,413 
3 out of 263 
3 out of 6,964 
Years Active: 1978-2026
Title: Innovator Hiroshi Ochi: Pioneering Advances in Monoclonal Antibodies
Introduction
Hiroshi Ochi, a distinguished inventor based in Osaka, Japan, has made significant contributions to the field of biotechnology. With a remarkable portfolio of 10 patents, Ochi's work primarily focuses on the development of human anti-IL-33 neutralizing monoclonal antibodies, which hold promise for therapeutic applications targeting diseases associated with IL-33.
Latest Patents
Hiroshi Ochi's latest patents center around innovative approaches to designing monoclonal antibodies with antagonistic effects against IL-33. His inventive process includes isolating human anti-IL-33 neutralizing monoclonal antibodies, employing framework regions with specific amino acid sequences derived from germline compositions. By identifying epitopes and enhancing binding capabilities through targeted mutations in the complementarity-determining regions, Ochi's work advances the potential for effective treatments in immunology.
Career Highlights
Throughout his career, Ochi has been associated with prominent companies such as Funai Electric Company Ltd. and Sumitomo Chemical Company Limited. His tenure at these institutions has allowed him to contribute significantly to research and development in antibody engineering and biotechnology.
Collaborations
Moreover, Hiroshi Ochi has collaborated with notable coworkers, including Hiroshi Ohtsuka and Shinichi Yokota. These partnerships have fostered innovation and expanded the scope of research in antibody therapeutics, further solidifying Ochi's reputation in the scientific community.
Conclusion
In summary, Hiroshi Ochi's inventive endeavors in the realm of human anti-IL-33 neutralizing monoclonal antibodies exemplify the groundbreaking advancements in biotechnology. His patents not only reflect a dedication to scientific research but also serve as a foundation for future therapeutic developments aimed at optimizing immune responses. His work continues to inspire innovation in the field, paving the way for new diagnostic and treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile